Raloxifene Has No Efficacy in Reducing the High Bone Turnover and the Risk of Spontaneous Vertebral Fractures after Denosumab Discontinuation

Abstract EN

At denosumab discontinuation, an antiresorptive agent is prescribed to reduce the high bone turnover, the rapid bone loss, and the risk of spontaneous vertebral fractures.

We report the case of a woman treated with aromatase inhibitors and denosumab for 5 years.

Raloxifene was then prescribed to prevent the rebound effect.

Raloxifene was ineffective to reduce the high bone turnover and to avoid spontaneous clinical vertebral fractures.

We believe that among the antiresorptive treatments, the most powerful bisphosphonates should be favored, and their administration adapted according to the serial follow-up of bone markers.